F/m Emerald Life Sciences Innovation ETF (NASDAQ:LFSC – Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 5,613 shares, a decline of 77.2% from the September 15th total of 24,651 shares. Based on an average daily trading volume, of 3,199 shares, the short-interest ratio is presently 1.8 days. Approximately 0.2% of the company’s stock are short sold.
F/m Emerald Life Sciences Innovation ETF Trading Down 2.8%
NASDAQ:LFSC traded down $1.18 during midday trading on Tuesday, reaching $41.43. 801 shares of the stock traded hands, compared to its average volume of 4,299. F/m Emerald Life Sciences Innovation ETF has a 12-month low of $29.55 and a 12-month high of $48.78. The business has a 50-day moving average of $45.67 and a two-hundred day moving average of $42.18.
Hedge Funds Weigh In On F/m Emerald Life Sciences Innovation ETF
A hedge fund recently raised its stake in F/m Emerald Life Sciences Innovation ETF stock. Hunter Associates Investment Management LLC increased its holdings in shares of F/m Emerald Life Sciences Innovation ETF (NASDAQ:LFSC – Free Report) by 8.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,739 shares of the company’s stock after buying an additional 3,831 shares during the quarter. Hunter Associates Investment Management LLC owned 1.86% of F/m Emerald Life Sciences Innovation ETF worth $1,736,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
F/m Emerald Life Sciences Innovation ETF Company Profile
The F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.
See Also
- Five stocks we like better than F/m Emerald Life Sciences Innovation ETF
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
- JPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength
Receive News & Ratings for F/m Emerald Life Sciences Innovation ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F/m Emerald Life Sciences Innovation ETF and related companies with MarketBeat.com's FREE daily email newsletter.
